Skip to main content
Premium Trial:

Request an Annual Quote

Agilent and Battelle to Co-Develop LC/MS Protein Identification Technology

NEW YORK, July 14 - Agilent Technologies said today that it has signed a Cooperative Research and Development Agreement (CRADA) with Battelle Memorial Institute to develop technology for protein identification using artificial neural networks.

 

Battelle is the operating and management contractor for the Department of Energy's Pacific Northwest National Laboratory, where the protein identification technology was initially developed.

 

Under the terms of the CRADA, Agilent and PNNL will adapt the technology to Agilent's liquid chromatograph/mass spectrometer systems.

 

The company said it expects the new protein identification method -- which uses artificial neural networks to predict how long it takes individual peptides to elute from a liquid chromatograph -- to offer improved statistical confidence compared to existing methods. According to PNNL, tests conducted in its William R. Wiley Environmental Molecular Sciences Laboratory showed that the predicted retention times match actual retention times to within approximately 3 percent.

 

"The elution prediction model adds another significant metric to peptide identification which can increase accuracy or alternatively, reduce the need for high-mass measurement accuracy in mass spectrometry proteomics," said Richard Smith, laboratory fellow at PNNL, in a statement.

 

Under the CRADA, PNNL will demonstrate the peptide retention time capability on Agilent's instruments, and Agilent has the option to negotiate an exclusive license for the Battelle-owned background intellectual property and any inventions that may arise under the collaboration.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.